Cargando…
Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic
Autores principales: | Marzo-Ortega, Helena, Tan, Ai Lyn, Bissell, Lesley-Anne, Morgan, Ann W, Vandevelde, Claire, Vital, Edward M, Dass, Shouvik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263817/ https://www.ncbi.nlm.nih.gov/pubmed/32835240 http://dx.doi.org/10.1016/S2665-9913(20)30163-6 |
Ejemplares similares
-
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023) -
Counselling services embedded within rheumatology clinics could help bridge the gap in mental health care provision for adults with rheumatic diseases
por: Hayward, Georgia, et al.
Publicado: (2022) -
BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management
por: Marzo-Ortega, Helena, et al.
Publicado: (2020) -
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020) -
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)